Current Report Filing (8-k)
September 20 2016 - 2:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
September 15, 2016
Date of report (date of earliest event
reported)
MusclePharm Corporation
(Exact name of registrant as specified
in its charter)
Nevada
|
|
000-53166
|
|
77-0664193
|
(State or other jurisdictions of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Nos.)
|
4721 Ironton Street, Building A
Denver, Colorado 80239
(Address of principal
executive offices) (Zip Code)
(303) 396-6100
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrants under any of the following provisions:
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 5.02
|
Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On September 15, 2016, MusclePharm Corporation (the “Company”) announced that, effective as of such date, Mr. John Price
voluntarily resigned from his position as Chief Financial Officer of the Company. The Company has engaged a search firm to conduct a search for a new
full-time Chief Financial Officer.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
MUSCLEPHARM CORPORATION
|
|
|
|
|
|
By:
|
/s/
Ryan Drexler
|
|
|
|
Name: Ryan Drexler
|
|
|
|
Title: Interim
Chief Executive Officer
|
|
Date: September 20, 2016
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Apr 2024 to May 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Muscle Pharm Corporation (CE) (OTCMarkets): 0 recent articles
More Musclepharm Corp News Articles